STRENGTHENING HUMAN IMMUNITY USING ROBUST ANTIBODY THERAPIES
SparX Biopharmaceutical Corp.
Cure Cancer by Targeting Multiple Pathways with the Right Therapeutic Strategy
SparX Techologies
SAILINGTM
An integrated approach to discovering and building antibodies​
SYNMABTM
Design, Selection, Optimization of multi-specific antibodies​
SPARX BIFUNCTIONAL ADC PLATFORM
Universally empowering ADCs with high specificity, sensitivity and activity​
SparX Capabilities
News
SparX Biopharmaceutical Corp Announces Research Agreement with Mitsubishi Tanabe Pharma America to Advance Novel Antibody-Drug Conjugates
Chicago, March 31, 2025 /PRNewswire/ – SparX Biopharmaceutical Corp (“SparX”), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced the signing of
SparX to Present Phase 1 Clinical Updates of SPX-303, a Dual Checkpoint Bispecific Antibody, at Two Events During AACR 2025
Chicago, USA – SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress poster session at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 28, from 2:00 PM to 5:00 PM.
SparX Presents Nab2-ADC, a Groundbreaking Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate at BIO Asia-Taiwan 2024
Chicago, USA – SparX is thrilled to officially unveil its groundbreaking Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate (Nab2-ADC), a pioneering development poised to revolutionize
SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has
SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug
The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance
Get in Touch with SparX
- 700 E. Business Center Dr. Mount Prospect, IL 60056
- +1 847 257 7910 (Direct)
- +1 224 580 2979 (extension)
- info@sparxbio.com
